COMPTON, England--(BUSINESS WIRE)--To support the needs of vulnerable, preterm infants (less than 37 weeks gestation age) who are at high risk for malnutrition1, Baxter International Inc. (NYSE: BAX) today announced it has received Marketing Authorization from the Competent Authorities in the United Kingdom and Denmark for NUMETA G13E 300 mL, a parenteral (intravenous) nutrition (PN) product. These national approvals are the first of 20 European countries where Baxter is seeking authorization for NUMETA G13E in 2016.

NUMETA G13E is indicated for PN administration for neonatal patients when oral or enteral nutrition is impossible, insufficient or contraindicated. NUMETA addresses an important medical need to support neonatal patients who have acute nutritional requirements by providing a balanced formulation of amino acids (protein), glucose (carbohydrates), lipids (fats) and electrolytes in a triple-chamber system that was pioneered by Baxter.

''The early hours and days of a preterm infant’s life are critical, as neonates are at high risk for infection and malnutrition,'' said Mark DeLegge, M.D., senior medical director, Baxter. ''Baxter has developed a well-balanced solution to help meet the nutritional needs of these patients in the hospital with a triple-chamber system that simplifies the preparation process for healthcare workers and reduces the risk to patients of infection and dosing errors.''
NUMETA G13E is designed for activation and administration at the point of care. Research indicates ready-to-use PN may reduce the potential risk of medication errors and associated infections.2 NUMETA G13E was reformulated to meet the current pediatric nutritional guidelines developed by the European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and the European Society for Clinical Nutrition and Metabolism (ESPEN).

''Parenteral nutrition in the hospital is an essential component of providing safe and effective nutrition for seriously ill patients,'' said Brik Eyre, president of Baxter's Hospital Products business. ''Baxter’s innovations to support efficiency in hospital pharmacies, coupled with its expertise in sterile manufacturing and container technology, helps bring safety to the patient’s bedside while increasing efficiency for clinicians who administer treatment.''

Baxter offers additional pediatric triple-chamber PN solutions, including NUMETA G16E 500mL for term infants and toddlers (term infants through two years of age); and NUMETA G19E 1,000mL for children and adolescents (2-18 years of age), which were introduced in 2011.

European Press Room Homepage